PO.CL05.10 · 临床研究

Immune microenvironmental patterns in rapidly progressive young-onset tongue cancer: A case series analysis

海报缩略图:Immune microenvironmental patterns in rapidly progressive young-onset tongue cancer: A case series analysis
编号 7928 展板 3 时间 4/22 09:00–12:00 区域 Section 49 主讲 Takahiro Tsujikawa, MD;PhD
分会场 Tumor Microenvironment Modulators
查看完整资料 下载 PDF 登录后可访问当前开放资料 AACR 官方页面 ↗

作者与单位

Alisa Kimura1, Takahiro Tsujikawa1, Shota Sugaya2, Yuna van der Aar2, Koichi Yoshizawa2, Sumiyo Saburi2, Shigeyuki Mukudai2, Hikaru Nagao2, Aki Tamura2, Nana Sakurai2, Aya Miyagawa-Hayashino3, Hiroshi Ogi4, Saya Shibata4, Eiichi Konishi2, Kyoko Itoh3, Shigeru Hirano1

1Department of Otolaryngology–Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan,2Kyoto Prefectural University of Medicine, Kyoto, Japan,3Department of Pathology and Applied Biology, Kyoto Prefectural University of Medicine, Kyoto, Japan,4SCREEN Holdings Co., Ltd., Kyoto, Japan

摘要 Abstract

Young-onset tongue cancer is increasingly recognized as a distinct clinical entity, differing from conventional tongue cancer associated with alcohol and tobacco use in terms of risk factors, clinical behavior, and molecular alterations. In rapidly progressive cases, delayed diagnosis and therapeutic challenges have been highlighted. Prior studies have implicated a myeloid-inflamed tumor microenvironment in this subset, suggesting that unique immune landscapes may influence diseases trajectories and treatment response. We analyzed five cases of rapidly progressive young-onset tongue cancer, focusing on clinical characteristics, genetic alterations, and immune tumor microenvironmental features assessed by 14-marker multiplex immunohistochemistry. Patients ranged from 22 to 48 years (median, 40 years), with a median time to recurrence of three months following initial treatment. Three of 5 patients had no history of alcohol or tobacco use. TERT promoter mutation were identified in two cases. All tumors exhibited abundant tumor-associated macrophages. CD8 + T cell infiltration showed inter-case variability, ranging from sparse to dense. However, in contrast to non-young-onset tongue cancer tissues, CD8 + T cells in young-onset cases were frequently excluded from tumor cell nests, even in specimens with high overall infiltration. These findings suggest the presence of immune exclusion mechanisms underlying the rapid progression of young-onset tongue cancer. Immune exclusion may represent a key barrier to effective immunotherapy in this population and warrants further investigation as a therapeutic target.
利益披露 Disclosure
A. Kimura, None. T. Tsujikawa, Merck Biopharma Independent Contractor. Rakuten Medical Independent Contractor. Bristol-Myers Squibb Independent Contractor. Eisai Co., Ltd. Independent Contractor. Merck Sharp & Dohme Corp Independent Contractor. Ono Pharmaceutical Independent Contractor. S. Sugaya, None.. Y. van der Aar, None.. K. Yoshizawa, None.. S. Saburi, None.. S. Mukudai, None.. H. Nagao, None.. A. Tamura, None.. N. Sakurai, None.. A. Miyagawa-Hayashino, None. H. Ogi, SCREEN Holdings Co., Ltd. Employment. S. Shibata, SCREEN Holdings Co., Ltd. Employment. E. Konishi, Chugai Pharmaceuticals Independent Contractor. K. Itoh, None.. S. Hirano, None.

在会议检索中打开